A leading contributor of science and knowledge through discoveries.
Currently Not Accepting Students.
Assistant Professor in Department of Immunology, and Department of Internal Medicine section of Gastroneterology, University of Manitoba; Researcher, Children’s Hospital Research Institute of Manitoba; Director of the Gastrointestinal Basic Biology Research at the Inflammatory Bowel Disease Clinical & Research Centre, University of Manitoba
Inflammatory bowel disease (IBD) are idiopathic, chronic intestinal disorders of complex pathogenesis and involve an aberrant immune response to some environmental antigen in genetically predisposed adults and children. Current treatments for IBD address the symptoms and are not curative, and they have potentially serious side effects. Thus, new, effective and safer therapies are required.
The primary mission of my laboratory is to develop novel therapeutic strategies in this field. My research interests have mainly been in the areas of neuroinflammatory mechanisms and neuroendocrine peptides. I have extensive research training at world-renowned institutes. Building upon my expertise in gut neuro-inflammation, my laboratory is exploring the role of neuroimmunoendocrine regulation during the development of gastrointestinal inflammation and is elucidating the mechanisms involved in the evolution of the gut maintaining its normal immune homeostasis to developing chronic gastrointestinal inflammatory disease.
Our research is divided in four novel innovative programs:
The goal of this innovative and high impact study is to demonstrate that the widespread use and potential impact of neural modulation (e.g. use of anti-depressant and pharmacological stimulation of the vagus nerve) may be important therapeutic adjuncts to the conventional approach in IBD.
iii) Third, semaphorin 3E (Sema3E) has emerged as an new essential axis involved in the dendritic cell immunoinflammatory response; however, the role of Sema3E in IBD is unknown and we will continue to explore its role in the context of chronic quiescent colitis and in IBD. Our data demonstrated that Sema3E could be a protein of interest in developing new treatments for patients with IBD.
All four studies are highly novel as they will not only demonstrate the role of new drugs or proteins of interest in animal models of colitis, but in a translational perspective, using clinical samples, they will expand their roles in the clinical context of IBD.